<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491606</url>
  </required_header>
  <id_info>
    <org_study_id>A-7540</org_study_id>
    <nct_id>NCT02491606</nct_id>
  </id_info>
  <brief_title>Evaluation of Weekly Tafenoquine</brief_title>
  <official_title>Evaluation of Weekly Tafenoquine (SB 252263 / WR 238605) Compared to Placebo for Chemosuppression of Plasmodium Falciparum in Western Kenya</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SmithKline Beecham</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 2b, placebo controlled, randomized, blinded study of the efficacy of WR
      238605, a new primaquine analog, compared to placebo as chemosuppression of P. falciparum
      malaria in Nyanza Province, western Kenya.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 1997</start_date>
  <completion_date type="Actual">September 1998</completion_date>
  <primary_completion_date type="Actual">September 1997</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prophylactic outcome.</measure>
    <time_frame>13 Weeks</time_frame>
    <description>Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells.
A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prophylactic outcome after 7 weeks</measure>
    <time_frame>7 Weeks</time_frame>
    <description>Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells.
A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prophylactic outcome after 10 weeks</measure>
    <time_frame>10 Weeks</time_frame>
    <description>Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells.
A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Load only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading with tafenoquine 400 mg base for three days followed by placebo weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low weekly dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High weekly dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading with placebo for 3 days followed by placebo once weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tafenoquine</intervention_name>
    <description>Tafenoquine 200mg and 400 mg</description>
    <arm_group_label>Load only</arm_group_label>
    <arm_group_label>Low weekly dose</arm_group_label>
    <arm_group_label>High weekly dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subjects (male or female)

          2. Age of 18-55 years

          3. Residing in one of the study villages of the Nyanza Province for the entire study

        Exclusion Criteria:

          1. Any cardiovascular, liver, neurologic, or renal functional abnormality which in the
             opinion of the clinical investigators would place the subject at increased risk of an
             adverse event or confuse the result.

          2. Female subjects who were pregnant (Positive serum / plasma -HCG as tested within 48
             hours of first drug administration).

          3. Use of antimalarial drugs not prescribed by study physicians within 2 weeks of study
             drug initiation.

          4. Clinically significant abnormalities (including but not limited to abnormal hepatic or
             renal function) as determined by history, physical and routine blood chemistries and
             complete blood count.

          5. Known hypersensitivity to any study drug.

          6. Unwilling to remain in area and report for drug administration and blood drawing
             during the duration of the study.

          7. Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A.J Oloo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya Medical Research Institute</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>July 2, 2015</last_update_submitted>
  <last_update_submitted_qc>July 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tafenoquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

